Objectives: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods that allow accurate quantitation of thyroglobulin (Tg) in the presence of Tg antibodies (TgAbs) have recently become available. Due to cost differences between LC-MS/MS and immunoassay, some laboratories now offer a reflex test strategy that uses LC-MS/MS only for TgAb-positive samples. The goal of this study was to examine utilization of Tg testing strategies and cost savings.
Conclusions: Identifying situations to use more expensive testing methods (eg, LC-MS/MS) only when necessary, such as for TgAb-positive patients, leads to considerable cost savings and a more economical use of valuable health care resources.
Thyroglobulin (Tg) is a glycoprotein produced only by the thyroid gland and serves as a precursor to the thyroid hormones thyroxine and triiodothyronine. After treatment of thyroid cancer by thyroid removal and/or ablative treatment with radioactive iodide, Tg concentrations are expected to drop to very low or undetectable levels. As increasing Tg concentrations may indicate residual tumor or cancer recurrence, Tg testing is currently recommended for monitoring of patients with thyroid cancer. [1] [2] [3] The American Thyroid Association (ATA) guidelines suggest that serum Tg measurements are repeated every 6 to 12 months after thyroid removal using an immunometric assay calibrated against the human thyroglobulin certified reference material (CRM-457). 1 Since thyroid cancer is the most rapidly increasing type of cancer in the United States, 4, 5 possibly due to increased diagnosis, 6 demand for testing is increasing as well. The fact that thyroid cancer is usually
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Exam is located at www.ascp.org/ajcpcme. [20] [21] [22] Specifically, discrepancy between IA and LC-MS/MS in samples with Tg concentrations less than 2 mg/L has been reported. 21 Comparisons in TgAb-negative patients revealed comparable performance and no significant bias between LC-MS/MS and Tg IA. 20, 21 Studies have also shown good agreement between different LC-MS/MS methods in both TgAb-positive and TgAb-negative patients. 21, 23 The goal of this study was to examine utilization of Tg and TgAb testing from more than 150,000 orders from our laboratory and perform a cost analysis to determine the potential savings from employing a reflex testing strategy, as well as health care dollars potentially wasted when not ordering by reflex testing. This has important implications for patient care as well as management of health care monies and resources.
Materials and Methods

Data Collection
Data were obtained from samples previously submitted for testing at ARUP Laboratories (Salt Lake City, UT). All studies involving the use of human specimens were approved by the University of Utah Institutional Review Board (IRB 00007275). Data were obtained using two different approaches. In the first data set, all patient samples submitted for either TgAb or Tg testing, by any method, were included for the timeframe chosen. This represented 150,623 orders (99,693 unique patients and 147,583 unique accession numbers). This data set was also used to assess the number of patients for whom a TgAb status change (negative to positive or positive to negative) occurred. For the second data set, patients for whom Tg by LC-MS/MS was ordered with a separate TgAb order on the same or a previous date were chosen. This set of data included 1,971 unique Tg by LC-MS/MS orders.
Cost Analysis
Since Tg measurement by LC-MS/MS has become commercially available, a commonly offered reflex testing strategy involves first testing samples for TgAb by IA. If positive for TgAb, then Tg is measured using LC-MS/MS; if negative for TgAb, Tg is measured using IA Figure 1 . Alternately, Tg measurement by LC-MS/MS may be ordered directly without TgAb measurement.
To evaluate the costs associated with these different testing strategies, cost analysis was performed by collecting commercial list prices for Tg by IA (TgIA), Tg by LC-MS/ MS (TgMS), TgAb, and Tg ordered by a reflex testing strategy (TgReflex) from three different US-based laboratories that currently offer these methods. This pricing does not represent any group or high-volume discounts that may be available to certain clients. These prices were averaged and used as the basis for subsequent calculations.
Measurement of Analytes
TgAb
In the first data set, TgAb had been measured using the Beckman Coulter DxI 800 (Access Anti-Tg Antibody II assay; Beckman Coulter, Brea, CA) according to the manufacturer's instructions. This is a sequential two-step immunoenzymatic assay that uses a streptavidin-coated paramagnetic particle coupled with human biotinylated thyroglobulin and a chemiluminescent substrate. Samples were collected in serum separator tubes or heparin tubes and stored refrigerated at 2 C to 4 C. The analytical measurement range (AMR) for this assay was 0.9 to 2,200.0 IU/mL. In routine use, between-run coefficient of variation (CV) averaged 7.4% at 5.0 IU/mL and 7.3% at 188.3 IU/mL for multiple instruments. A value of 4.0 IU/mL or less indicated a negative result for TgAb. For the second data set, TgAb results were previously obtained with the method listed above or the Siemens IMMULITE 2000 analyzer (Anti-Tg assay; Siemens, Tarrytown, NY) according to the manufacturer's instructions. This assay uses a two-site immunoassay with a Tg-coated bead and a mouse monoclonal anti-human immunoglobulin G conjugated to alkaline phosphatase. Sample collection and storage were as above. The AMR was 20.0 to 3,000.0 IU/mL with a between-run CV of 5.0% at 44.1 IU/mL and 3.9% at 262 IU/mL. Using this assay, a value of 20.0 IU/mL or less indicated a negative result for TgAb.
TgIA
TgIA was performed using the Beckman Coulter DxI 800 (Access Tg assay) according to the manufacturer's instructions. Samples were collected in serum separator tubes or heparin tubes and stored refrigerated (2-4 C). This is a one-step immunoenzymatic assay with a biotinylated mixture of four monoclonal anti-Tg antibodies, streptavidincoated paramagnetic particles, and a monoclonal anti-Tg antibody alkaline phosphatase conjugate. A chemiluminescent substrate was used and relative light units were proportional to the Tg concentration. The AMR was 0.1 to 500.0 mg/L. Higher values may be quantified, up to 303,000 mg/L, by dilution with the manufacturer's diluent. In routine use, between-run CV averaged 6.4% at 11.3 mg/L and 6.6% at 83.0 mg/L for multiple instruments. The reference interval in our laboratory is stratified by age (mg/L): 6 months to 3 years (7.4-48.7), 4 to 7 years (4.1-40.5), 8 to 17 years (0.8-29.4), and 18 years and older (1.3-31.8).
TgMS
The method of TgMS used at ARUP Laboratories has been described previously. 21 This method involves trypsin digestion and quantitation of a specific Tg peptide after its capture by a sequence-specific antibody. For these data, samples were collected in serum separator tubes or in heparin or EDTA plasma tubes and refrigerated (2-4 C). Briefly, patient serum was treated with a mixture of anti-Tg antibodies, then precipitated and digested with trypsin. A unique Tg peptide was captured using a specific antibody, and multiple-reaction monitoring was used to identify and quantitate Tg. A 5-point calibration curve prepared using commercial calibrators (Beckman Coulter) was made with every batch of samples. Analyst software (v.1.5.2 or newer; SCIEX, Framingham, MA) was used. The limit of quantitation and limit of detection of this method were 0.5 and 0.25 mg/L, respectively. The method was linear up to 1,045 mg/L, and the between-run CV was less than 6.0% at all concentrations evaluated. The reference interval in our laboratory was stratified by age, with the ranges the same as for the TgIA method previously stated.
Results
Utilization
A common reflex strategy used for Tg testing is shown in Figure 1 . For the first data set (150,623 orders), there were 90,312 TgReflex orders Table 1 . A smaller number of orders (11,293) were for TgMS. The remainder of the orders in this data set (49,018) included orders for TgAb. Considering only the orders including Tg, 89% used the TgReflex order and 11% ordered TgMS directly. A small percentage of these orders was for both TgAb and TgMS (777/49,018; 1.6%) or TgAb and TgReflex (317/49,018; 0.6%) on the same sample.
Cost Analysis
As shown in Table 1 , the average TgReflex list price was $170 if the patient sample was TgAb negative and Tg was therefore measured by IA; if TgAb positive and Tg quantified by LC-MS/MS, the average TgReflex list price was $295. TgReflex orders included 90,312 patient samples. Of these, 80,385 were TgAb negative and thus Tg was measured by IA. The remaining samples were TgAb positive (9,926), and Tg concentrations were thus measured by LC-MS/MS. One TgAb-positive specimen was compromised and therefore not tested for Tg. To estimate cost savings since implementation of the TgReflex strategy, TgReflex cost for TgAb-negative patients was compared with the expected TgMS cost for the same number of samples. Table 2 shows that overall savings would be over $3.2 million for this period of testing. At list prices, this represents a savings of $40 for each Tg measurement. TgAb testing has been described as another way to monitor or stratify patients with thyroid cancer, with rapid decreases indicative of an excellent prognosis 12, 15, [24] [25] [26] ;
however, patients with very high TgAb at diagnosis may never become TgAb negative, 24 and guidelines still recommend Tg testing for these patients. Since some clinicians may follow both of these as separate markers, comparison of overall costs of TgReflex orders to separate orders for both TgAb and TgMS was also done. Table 2 shows that this would have resulted in a savings of over $9 million. For this comparison, a second set of data included only results for TgMS that had also (the same or previous date) ordered TgAb for that patient. A total of 1,971 unique orders met this criterion. Of these, 84% (1,663) were ordered on the same patient sample. Table 3 shows the costs associated with these results compared with costs if TgReflex had been used; costs for the TgAb-negative samples (1,517) are also shown. Overall, approximately $170,000 of potential savings were not realized.
Percentage of TgAb Positives and TgAb Status Change
The percentage of samples that were TgAb positive was examined in various testing populations Table 4 . There were three samples for which TgAb was not reported, so the total number of orders differs slightly from Table 1 . For the TgReflex orders, 9,926 were TgAb positive and 80,385 were TgAb negative, indicating that 89% of the samples tested using the reflex strategy were negative for TgAb. For the small pool of samples that ordered both TgMS and TgAb separately for the same patient sample, 91% were TgAb negative. For the TgAb orders, 85% were TgAb negative.
We also examined the percentage of patients in whom the TgAb result (status) changed from negative to positive or vice versa, thus switching to a different test platform for Tg per the TgReflex testing algorithm. From our first data set, there were 90,312 orders for TgReflex. However, to observe a status change, there would need to be two or more orders for a patient; in our data set, 19,147 patients met this criterion. Of these, 738 (3.9%) had a change in TgAb status, resulting in a change in testing platform during serial monitoring of Tg. Since a Tg concentration of 1.0 mg/L or below is often used in clinical decision making and is associated with excellent clinical outcomes and low recurrence rates, 3 we examined the number of these 738 patients with Tg of 1.0 mg/L or less. In total, 131 patients (0.68% of TgReflex tests ordered two or more times) fell into this range.
Discussion
Since the emergence of Tg testing by LC-MS/MS, several commercial laboratories now offer reflex testing options for Tg in which all samples are first tested for TgAb. Samples that are TgAb positive have Tg quantitated by LC-MS/MS to avoid interference from TgAb in the patient sample. Samples that are TgAb negative have Tg measured using IA, which is comparable to LC-MS/MS when TgAb is not present. [19] [20] [21] [22] [23] 27 In this study, the focus was to understand which ordering option was being used most often and TgAb, thyroglobulin antibody; TgMS, thyroglobulin testing using liquid chromatography-tandem mass spectrometry; TgReflex, thyroglobulin testing using reflex strategy. examine whether cost savings may result from reflex testing. Most Tg orders (89%) to our laboratory used TgReflex. Of these samples, only 11% were TgAb positive. Cost savings are realized for TgAb-negative samples since TgIA is a lower cost method than LC-MS/MS. As shown in Table 2 , using the average list price obtained from three different laboratories showed that, for this data set, TgReflex saved over $3 million compared with the cost of using the more expensive LC-MS/MS method without considering a patient's TgAb status. If one were to compare the overall cost difference between TgReflex compared with separately ordering both TgAb and TgMS, then the savings realized would be much more ($9 million). While current guidelines do not comment on the utility of TgAb measurements on their own, several studies have suggested that following trends in TgAb values can be used to monitor thyroid cancer in TgAb-positive patients. 12, 15, 25, 26, [28] [29] [30] Although there are multiple reasons for ordering TgAb, there were 1,971 unique orders for which both Tg by LC-MS/MS and TgAb were ordered on the same patient. These could be from physicians choosing to monitor both Tg and TgAb in their patient. However, 1,517 (91%) were TgAb negative. Thus, it is likely these orders represent clients not properly using the TgReflex option. Since TgAb status typically changes quite slowly, approximately 11% (IU/mL) per month according to one recent study, 31 While a change in TgAb status using the TgReflex method will result in a change in Tg testing platform, this happens infrequently based on data used for this study. Of patients with a TgAb status change, less than 1% of patients for whom status change was observed had Tg values in the range that might affect clinical decision making. However, providers need to be aware that different testing platforms for either Tg or TgAb may give somewhat different values and should be cautious in their interpretation when Tg results are near the recommended cutoff values. To date, the best approach for patient follow-up of these patients still includes both biochemical and radiologic approaches, so Tg results are not the sole determination of patient management. 33 In summary, most clinicians used the Tg reflex option, which resulted in tremendous cost savings since, according to our data, only approximately 10% to 15% of patients were TgAb positive. A small percentage of orders were for TgAb and TgMS separately when the antibody status was either unknown (ordered the same day) or was previously determined to be negative, resulting in unnecessary utilization of the more expensive LC-MS/MS testing. These data provide a current example that identifying situations in which using more expensive testing methods (eg, LC-MS/MS) is most appropriate, such as for TgAb-positive patients, leads to a more economical use of valuable health care resources.
